Join Growin Stock Community!

Mesa laboratories, inc.MLAB.US Overview

US StockTechnology
(No presentation for MLAB)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MLAB AI Insights

MLAB Overall Performance

MLAB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MLAB Recent Performance

-3.45%

Mesa laboratories, inc.

0.66%

Avg of Sector

-0.31%

S&P500

MLAB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MLAB Key Information

MLAB Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MLAB Profile

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Price of MLAB

MLAB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MLAB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.68
PE Ratio (TTM)
148.57
Forward PE
59.51
PS Ratio (TTM)
2.16
PB Ratio
2.83
Price-to-FCF
13.58
METRIC
VALUE
vs. INDUSTRY
Gross Margin
62.40%
Net Margin
1.51%
Revenue Growth (YoY)
4.12%
Profit Growth (YoY)
3.67%
3-Year Revenue Growth
6.26%
3-Year Profit Growth
8.45%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.68
PE Ratio (TTM)
148.57
Forward PE
59.51
PS Ratio (TTM)
2.16
PB Ratio
2.83
Price-to-FCF
13.58
Gross Margin
62.40%
Net Margin
1.51%
Revenue Growth (YoY)
4.12%
Profit Growth (YoY)
3.67%
3-Year Revenue Growth
6.26%
3-Year Profit Growth
8.45%

  • When is MLAB's latest earnings report released?

    The most recent financial report for Mesa laboratories, inc. (MLAB) covers the period of 2026Q3 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MLAB's short-term business performance and financial health. For the latest updates on MLAB's earnings releases, visit this page regularly.

  • Where does MLAB fall in the P/E River chart?

    According to historical valuation range analysis, Mesa laboratories, inc. (MLAB)'s current price-to-earnings (P/E) ratio is 129.51, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of MLAB?

    According to the latest financial report, Mesa laboratories, inc. (MLAB) reported an Operating Profit of 7.98M with an Operating Margin of 12.25% this period, representing a growth of 38% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is MLAB's revenue growth?

    In the latest financial report, Mesa laboratories, inc. (MLAB) announced revenue of 65.13M, with a Year-Over-Year growth rate of 3.64%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does MLAB have?

    As of the end of the reporting period, Mesa laboratories, inc. (MLAB) had total debt of 166.13M, with a debt ratio of 0.38. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does MLAB have?

    At the end of the period, Mesa laboratories, inc. (MLAB) held Total Cash and Cash Equivalents of 28.98M, accounting for 0.07 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does MLAB go with three margins increasing?

    In the latest report, Mesa laboratories, inc. (MLAB) achieved the “three margins increasing” benchmark, with a gross margin of 64.2%%, operating margin of 12.25%%, and net margin of 5.6%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess MLAB's profit trajectory and future growth potential.

  • Is MLAB's EPS continuing to grow?

    According to the past four quarterly reports, Mesa laboratories, inc. (MLAB)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.66. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MLAB?

    Mesa laboratories, inc. (MLAB)'s Free Cash Flow (FCF) for the period is 18.02M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 2.25% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of MLAB?

    The latest valuation data shows Mesa laboratories, inc. (MLAB) has a Price-To-Earnings (PE) ratio of 129.51 and a Price/Earnings-To-Growth (PEG) ratio of 0.64. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.